



## COVID-19 Vaccine-Associated Autoimmune Diseases and Disorders

Guest Editor:

**Dr. Iftach Sagy**

Rheumatic Diseases Unit, Soroka  
University Medical Center, Beer  
Sheva, Israel

Deadline for manuscript  
submissions:

**30 November 2024**

### Message from the Guest Editor

Dear all,

The interplay between vaccines and autoimmunity is well known. Patients with autoimmune rheumatic diseases are of great concern regarding COVID-19 infection and vaccination. SLE patients have a higher risk for COVID-19-related complications, including mortality, compared to age and sex-adjusted controls and other autoimmune rheumatic disease conditions. On the other hand, the risk of autoimmune rheumatic disease flares following the COVID-19 vaccine has raised some concerns. However, overall COVID-19 vaccine appears to be safe among SLE patients, with a low rate of severe adverse effects. In addition, a new onset of autoimmune rheumatic diseases among previously healthy patients vaccinated against COVID-19 has recently emerged sporadically.

To improve the understanding of the relationship between vaccines and new diagnoses of autoimmune diseases, this special issue of *Vaccines* focuses on researching this phenomenon. We encourage researchers to contribute original studies, reports, and reviews of the epidemiology, molecular pathways, and clinical and management of newly onset autoimmune conditions related to vaccine uptake.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)